The FDA approved Novocure medical device Optune Luna as a treatment for advanced cases of non-small cell lung cancer. The wearable technology delivers electrical fields that kill cancer cells.
Novocure said its “Tumor Treating Fields” met the main goal of a pivotal study enrolling non-small cell lung cancer patients with brain metastases. However, results for the electricty-based treatment fell short of statistical significance on several secondary endpoints.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Novocure’s electrical field-producing medical device, in combination with standard drug therapies, improved overall survival in a pivotal study that enrolled patients with advanced non-small cell lung cancer. The medtech company now plans to seek regulatory approvals.
Almost no new therapies have succeeded in extending patient survival in GBM in the last 20 years, and the field is littered with drugs that have failed despite promising early data. But researchers soldier on with new molecular targets and therapeutic modalities.
On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.
Also, Merck's drug, Bridion, which reverses the effects of muscle relaxants used during surgery has won U.S. approval.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.